JPMorgan analyst Alexei Gogolev raised the firm’s price target on HealthEquity (HQY) to $126 from $125 and keeps an Overweight rating on the shares. The company reported solid Q2 results despite labor market weakness, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HQY:
- Healthequity’s Strong Financial Performance and Strategic Initiatives Drive Buy Rating
- Healthequity’s Strong Financial Performance and Strategic Initiatives Justify Buy Rating
- Healthequity’s Strong Q2 Performance and Strategic Initiatives Justify Buy Rating
- HealthEquity, Inc. Reports Strong Q2 Financial Results
- Closing Bell Movers: Google jumps 7% on constructive antitrust ruling